Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer Blackrock
Entity holding fund iShares IV Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF Ticker BTEC(USD) LSE
ETF Ticker BTEK(GBP) LSE
ETF Ticker 2B70(EUR) F
ETF Ticker 2B70.DE(EUR) CXE
ETF Ticker BTEC.LS(USD) CXE
ETF Ticker BTEK.LS(GBP) CXE
ETF Ticker BTEC.L(GBP) LSE
ETF Ticker BTEK.L(GBP) LSE

Holdings detail for MLYS

Stock Name	Mineralys Therapeutics, Inc. Common Stock
Ticker	MLYS(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US6031701013

Show aggregate MLYS holdings

News associated with MLYS

Mineralys Therapeutics (NASDAQ:MLYS) Sees Strong Trading Volume on Analyst Upgrade: Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) shares saw unusually-high trading volume on Thursday after Wells Fargo & Company raised their price target on the stock from $26.00 to $50.00. Wells Fargo & Company currently has an overweight rating on the stock. Approximately 792,595 shares changed hands during trading, a decline of 26% from […] - 2025-09-12 02:42:55
The Goldman Sachs Group Forecasts Strong Price Appreciation for Mineralys Therapeutics (NASDAQ:MLYS) Stock: Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) had its target price raised by equities researchers at The Goldman Sachs Group from $32.00 to $52.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. The Goldman Sachs Group’s target price points to a potential upside of […] - 2025-09-11 03:13:15
Mineralys Therapeutics Reaches Analyst Target Price: In recent trading, shares of Mineralys Therapeutics Inc (Symbol: MLYS) have crossed above the average analyst 12-month target price of $38.25, changing hands for $38.50/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgr - 2025-09-10 07:47:17
Mineralys Therapeutics (NASDAQ:MLYS) Receives “Buy” Rating from HC Wainwright: HC Wainwright restated their buy rating on shares of Mineralys Therapeutics (NASDAQ:MLYS – Free Report) in a research note released on Monday,Benzinga reports. The brokerage currently has a $42.00 target price on the stock. A number of other research firms have also weighed in on MLYS. Jefferies Financial Group raised their price target on shares […] - 2025-09-09 03:10:46
Mineralys Therapeutics (NASDAQ:MLYS) Price Target Raised to $26.00 at Jefferies Financial Group: Mineralys Therapeutics (NASDAQ:MLYS – Free Report) had its price objective hoisted by Jefferies Financial Group from $15.00 to $26.00 in a research report released on Wednesday morning,Benzinga reports. Jefferies Financial Group currently has a hold rating on the stock. A number of other research analysts have also recently commented on MLYS. Guggenheim set a $48.00 […] - 2025-09-04 05:16:51
Tuesday's ETF Movers: XBI, REMX: In trading on Tuesday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 3.2% on the day. Components of that ETF showing particular strength include shares of Mineralys Therapeutics, up about 87% and shares of Cytokinetics, up about 40.7% on the day. And under - 2025-09-02 15:05:25
Alps Advisors Inc. Sells 5,584 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS): Alps Advisors Inc. cut its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) by 13.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 34,664 shares of the company’s stock after selling 5,584 shares during the quarter. Alps […] - 2025-07-15 06:25:59
Head to Head Analysis: Mineralys Therapeutics (NASDAQ:MLYS) & Basilea Pharmaceutica (OTCMKTS:BPMUF): Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) and Basilea Pharmaceutica (OTCMKTS:BPMUF – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership. Profitability This table compares Mineralys Therapeutics and […] - 2025-07-08 05:06:49
Bank of America Corp DE Purchases 11,549 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS): Bank of America Corp DE raised its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) by 12.0% during the fourth quarter, Holdings Channel reports. The fund owned 107,703 shares of the company’s stock after buying an additional 11,549 shares during the period. Bank of America Corp DE’s holdings in Mineralys Therapeutics were worth $1,326,000 […] - 2025-06-06 04:34:57
10,405 Shares in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Acquired by ProShare Advisors LLC: ProShare Advisors LLC bought a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 10,405 shares of the company’s stock, valued at approximately $128,000. A number of other […] - 2025-06-03 04:50:50
Analysts Anticipate 16% Upside For IWV: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-06 08:37:26
Mineralys Therapeutics (NASDAQ:MLYS) Sees Strong Trading Volume on Analyst Upgrade: Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) saw strong trading volume on Wednesday after HC Wainwright raised their price target on the stock from $30.00 to $42.00. HC Wainwright currently has a buy rating on the stock. 303,503 shares were traded during trading, a decline of 17% from the previous session’s volume of 367,553 […] - 2025-04-04 02:17:07
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Bought by AlphaQuest LLC: AlphaQuest LLC boosted its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) by 2,637.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 15,222 shares of the company’s stock after purchasing an additional 14,666 shares during the period. AlphaQuest LLC’s holdings in Mineralys Therapeutics were worth $187,000 at the end of the […] - 2025-03-17 06:03:05
23,192 Shares in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Acquired by Proficio Capital Partners LLC: Proficio Capital Partners LLC purchased a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 23,192 shares of the company’s stock, valued at approximately $285,000. Other institutional investors and hedge funds have also bought and […] - 2025-03-12 05:14:51
HC Wainwright Reiterates Buy Rating for Mineralys Therapeutics (NASDAQ:MLYS): HC Wainwright restated their buy rating on shares of Mineralys Therapeutics (NASDAQ:MLYS – Free Report) in a report issued on Monday morning,Benzinga reports. The firm currently has a $30.00 price objective on the stock. MLYS has been the subject of several other research reports. Guggenheim restated a “buy” rating on shares of Mineralys Therapeutics in […] - 2025-03-11 04:40:47

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) MLYS holdings

Date	Number of MLYS Shares Held	Base Market Value of MLYS Shares	Local Market Value of MLYS Shares	Change in MLYS Shares Held	Change in MLYS Base Value	Current Price per MLYS Share Held	Previous Price per MLYS Share Held
2025-11-11 (Tuesday)	42,521	USD 2,003,164	USD 2,003,164	0	USD 110,979	USD 47.11	USD 44.5
2025-11-10 (Monday)	42,521	USD 1,892,185	USD 1,892,185	109	USD 279,681	USD 44.5	USD 38.02
2025-11-07 (Friday)	42,412	USD 1,612,504	USD 1,612,504	0	USD 42,836	USD 38.02	USD 37.01
2025-11-06 (Thursday)	42,412	USD 1,569,668	USD 1,569,668	109	USD -107,646	USD 37.01	USD 39.65
2025-11-05 (Wednesday)	42,303	USD 1,677,314	USD 1,677,314	0	USD -6,768	USD 39.65	USD 39.81
2025-11-04 (Tuesday)	42,303	USD 1,684,082	USD 1,684,082	109	USD 31,343	USD 39.81	USD 39.17
2025-11-03 (Monday)	42,194	USD 1,652,739	USD 1,652,739	0	USD -71,308	USD 39.17	USD 40.86
2025-10-31 (Friday)	42,194	USD 1,724,047	USD 1,724,047	0	USD -10,970	USD 40.86	USD 41.12
2025-10-30 (Thursday)	42,194	USD 1,735,017	USD 1,735,017	545	USD 63,226	USD 41.12	USD 40.14
2025-10-29 (Wednesday)	41,649	USD 1,671,791	USD 1,671,791	218	USD -13,208	USD 40.14	USD 40.67
2025-10-28 (Tuesday)	41,431	USD 1,684,999	USD 1,684,999	0	USD 4,558	USD 40.67	USD 40.56
2025-10-27 (Monday)	41,431	USD 1,680,441	USD 1,680,441	0	USD 27,344	USD 40.56	USD 39.9

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of MLYS by Blackrock for IE00BYXG2H39

Show aggregate share trades of MLYS

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 109 44.890 38.010 38.698 USD 4,218 17.33
2025-11-06 BUY 109 39.795 37.000 37.279 USD 4,063 17.12
2025-11-04 BUY 109 40.480 38.520 38.716 USD 4,220 16.89
2025-10-30 BUY 545 43.434 40.510 40.802 USD 22,237 16.52
2025-10-29 BUY 218 40.140 40.975 40.891 USD 8,914 16.39
2025-10-22 SELL -436 42.040 43.390 43.255 USD -18,859 15.73 Loss of -11,999 on sale
2025-10-20 BUY 218 44.160 44.400 44.376 USD 9,674 15.43
2025-10-17 BUY 545 43.560 43.895 43.862 USD 23,905 15.27
2025-10-15 BUY 872 43.350 44.380 44.277 USD 38,610 15.12
2025-10-03 BUY 763 38.060 40.910 40.625 USD 30,997 14.84
2025-10-02 BUY 109 40.460 40.470 40.469 USD 4,411 14.69
2025-09-30 BUY 218 37.920 40.180 39.954 USD 8,710 14.42
2025-09-26 BUY 218 39.990 40.210 40.188 USD 8,761 14.13
2025-09-25 BUY 218 38.510 39.020 38.969 USD 8,495 13.99
2025-09-24 SELL -905 38.870 39.140 39.113 USD -35,397 13.84 Loss of -22,871 on sale
2025-09-18 BUY 112 39.870 40.330 40.284 USD 4,512 13.69
2025-09-17 BUY 336 37.290 39.000 38.829 USD 13,047 13.55
2025-08-20 SELL -452 15.480 15.550 15.543 USD -7,025 13.38 Loss of -979 on sale
2025-07-30 BUY 448 14.490 15.150 15.084 USD 6,758 13.35
2025-07-17 SELL -224 14.340 14.470 14.457 USD -3,238 13.32 Loss of -255 on sale
2025-07-11 SELL -904 14.490 14.940 14.895 USD -13,465 13.28 Loss of -1,456 on sale
2025-07-07 BUY 339 13.530 14.700 14.583 USD 4,944 13.26
2025-07-02 BUY 6,215 14.300 14.540 14.516 USD 90,217 13.24
2025-06-20 BUY 8,171 13.480 14.090 14.029 USD 114,631 13.24
2025-06-11 BUY 170 15.550 16.165 16.104 USD 2,738 13.19
2025-06-10 BUY 170 16.030 16.668 16.604 USD 2,823 13.17
2025-06-04 SELL -85 15.520 16.430 16.339 USD -1,389 13.09 Loss of -276 on sale
2025-04-23 BUY 85 13.530 14.140 14.079 USD 1,197 12.45
2025-04-10 SELL -680 12.190 12.460 12.433 USD -8,454 12.36 Loss of -51 on sale
2025-04-08 SELL -85 11.770 12.750 12.652 USD -1,075 12.36 Loss of -25 on sale
2025-04-07 SELL -85 12.050 12.470 12.428 USD -1,056 12.36 Loss of -6 on sale
2025-04-04 SELL -425 12.400 13.490 13.381 USD -5,687 12.36 Loss of -433 on sale
2025-04-01 BUY 348 13.840 17.170 16.837 USD 5,859 12.32
2025-03-31 SELL -255 15.880 16.020 16.006 USD -4,082 12.28 Loss of -950 on sale
2025-03-21 BUY 1,694 16.870 17.262 17.223 USD 29,175 11.99
2025-03-14 SELL -1,296 14.250 14.400 14.385 USD -18,643 11.75 Loss of -3,419 on sale
2025-03-07 SELL -162 10.520 10.770 10.745 USD -1,741 11.63 Profit of 144 on sale
2025-03-04 SELL -81 9.920 10.000 9.992 USD -809 11.70 Profit of 138 on sale
2025-02-25 BUY 162 8.760 9.285 9.232 USD 1,496 11.91
2025-02-19 SELL -81 9.320 9.500 9.482 USD -768 12.09 Profit of 212 on sale
2025-02-13 BUY 240 10.200 10.670 10.623 USD 2,550 12.26
2025-02-12 BUY 80 10.630 11.090 11.044 USD 884 12.29
2025-02-11 BUY 320 9.660 9.700 9.696 USD 3,103 12.34
2024-12-30 SELL -2,671 12.520 12.905 12.866 USD -34,366 13.24 Profit of 996 on sale
2024-11-18 SELL -1,293 11.400 11.800 11.760 USD -15,206 13.79 Profit of 2,626 on sale
2024-11-08 SELL -86 14.040 14.610 14.553 USD -1,252 13.80 Loss of -65 on sale
2024-10-21 SELL -87 13.830 14.470 14.406 USD -1,253 0.00 Loss of -1,253 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	109	44.890	38.010	38.698	USD 4,218	17.33
2025-11-06	BUY	109	39.795	37.000	37.279	USD 4,063	17.12
2025-11-04	BUY	109	40.480	38.520	38.716	USD 4,220	16.89
2025-10-30	BUY	545	43.434	40.510	40.802	USD 22,237	16.52
2025-10-29	BUY	218	40.140	40.975	40.891	USD 8,914	16.39
2025-10-22	SELL	-436	42.040	43.390	43.255	USD -18,859	15.73 Loss of -11,999 on sale
2025-10-20	BUY	218	44.160	44.400	44.376	USD 9,674	15.43
2025-10-17	BUY	545	43.560	43.895	43.862	USD 23,905	15.27
2025-10-15	BUY	872	43.350	44.380	44.277	USD 38,610	15.12
2025-10-03	BUY	763	38.060	40.910	40.625	USD 30,997	14.84
2025-10-02	BUY	109	40.460	40.470	40.469	USD 4,411	14.69
2025-09-30	BUY	218	37.920	40.180	39.954	USD 8,710	14.42
2025-09-26	BUY	218	39.990	40.210	40.188	USD 8,761	14.13
2025-09-25	BUY	218	38.510	39.020	38.969	USD 8,495	13.99
2025-09-24	SELL	-905	38.870	39.140	39.113	USD -35,397	13.84 Loss of -22,871 on sale
2025-09-18	BUY	112	39.870	40.330	40.284	USD 4,512	13.69
2025-09-17	BUY	336	37.290	39.000	38.829	USD 13,047	13.55
2025-08-20	SELL	-452	15.480	15.550	15.543	USD -7,025	13.38 Loss of -979 on sale
2025-07-30	BUY	448	14.490	15.150	15.084	USD 6,758	13.35
2025-07-17	SELL	-224	14.340	14.470	14.457	USD -3,238	13.32 Loss of -255 on sale
2025-07-11	SELL	-904	14.490	14.940	14.895	USD -13,465	13.28 Loss of -1,456 on sale
2025-07-07	BUY	339	13.530	14.700	14.583	USD 4,944	13.26
2025-07-02	BUY	6,215	14.300	14.540	14.516	USD 90,217	13.24
2025-06-20	BUY	8,171	13.480	14.090	14.029	USD 114,631	13.24
2025-06-11	BUY	170	15.550	16.165	16.104	USD 2,738	13.19
2025-06-10	BUY	170	16.030	16.668	16.604	USD 2,823	13.17
2025-06-04	SELL	-85	15.520	16.430	16.339	USD -1,389	13.09 Loss of -276 on sale
2025-04-23	BUY	85	13.530	14.140	14.079	USD 1,197	12.45
2025-04-10	SELL	-680	12.190	12.460	12.433	USD -8,454	12.36 Loss of -51 on sale
2025-04-08	SELL	-85	11.770	12.750	12.652	USD -1,075	12.36 Loss of -25 on sale
2025-04-07	SELL	-85	12.050	12.470	12.428	USD -1,056	12.36 Loss of -6 on sale
2025-04-04	SELL	-425	12.400	13.490	13.381	USD -5,687	12.36 Loss of -433 on sale
2025-04-01	BUY	348	13.840	17.170	16.837	USD 5,859	12.32
2025-03-31	SELL	-255	15.880	16.020	16.006	USD -4,082	12.28 Loss of -950 on sale
2025-03-21	BUY	1,694	16.870	17.262	17.223	USD 29,175	11.99
2025-03-14	SELL	-1,296	14.250	14.400	14.385	USD -18,643	11.75 Loss of -3,419 on sale
2025-03-07	SELL	-162	10.520	10.770	10.745	USD -1,741	11.63 Profit of 144 on sale
2025-03-04	SELL	-81	9.920	10.000	9.992	USD -809	11.70 Profit of 138 on sale
2025-02-25	BUY	162	8.760	9.285	9.232	USD 1,496	11.91
2025-02-19	SELL	-81	9.320	9.500	9.482	USD -768	12.09 Profit of 212 on sale
2025-02-13	BUY	240	10.200	10.670	10.623	USD 2,550	12.26
2025-02-12	BUY	80	10.630	11.090	11.044	USD 884	12.29
2025-02-11	BUY	320	9.660	9.700	9.696	USD 3,103	12.34
2024-12-30	SELL	-2,671	12.520	12.905	12.866	USD -34,366	13.24 Profit of 996 on sale
2024-11-18	SELL	-1,293	11.400	11.800	11.760	USD -15,206	13.79 Profit of 2,626 on sale
2024-11-08	SELL	-86	14.040	14.610	14.553	USD -1,252	13.80 Loss of -65 on sale
2024-10-21	SELL	-87	13.830	14.470	14.406	USD -1,253	0.00 Loss of -1,253 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of MLYS

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	244,235	500	550,045	44.4%
2025-09-18	339,717	0	633,774	53.6%
2025-09-17	240,800	0	531,001	45.3%
2025-09-16	167,697	0	371,955	45.1%
2025-09-15	194,014	8,146	487,442	39.8%
2025-09-12	151,726	0	451,127	33.6%
2025-09-11	131,121	900	485,575	27.0%
2025-09-10	328,963	0	829,756	39.6%
2025-09-09	443,312	0	883,107	50.2%
2025-09-08	553,594	359	783,297	70.7%
2025-09-05	857,373	747	1,455,455	58.9%
2025-09-04	681,934	1,011	1,307,490	52.2%
2025-09-03	1,485,178	2,660	3,779,708	39.3%
2025-09-02	3,622,250	5,949	8,088,657	44.8%
2025-08-29	188,016	0	380,936	49.4%
2025-08-28	158,582	0	339,606	46.7%
2025-08-27	109,319	0	217,599	50.2%
2025-08-26	112,853	0	392,744	28.7%
2025-08-25	383,479	0	609,740	62.9%
2025-08-22	155,984	0	493,645	31.6%
2025-08-21	93,028	0	272,024	34.2%
2025-08-20	349,282	16	453,947	76.9%
2025-08-19	279,177	0	470,367	59.4%
2025-08-18	222,867	0	359,398	62.0%
2025-08-15	180,005	0	296,658	60.7%
2025-08-14	476,635	0	600,331	79.4%
2025-08-13	364,593	0	592,505	61.5%
2025-08-12	197,382	0	237,914	83.0%
2025-08-11	306,371	0	352,828	86.8%
2025-08-08	108,011	0	146,980	73.5%
2025-08-07	120,510	0	160,880	74.9%
2025-08-06	128,342	0	167,193	76.8%
2025-08-05	198,302	0	241,190	82.2%
2025-08-04	230,115	0	369,885	62.2%
2025-08-01	264,586	0	453,492	58.3%
2025-07-31	118,359	0	203,435	58.2%
2025-07-30	156,946	24,325	234,612	66.9%
2025-07-29	179,629	100	246,714	72.8%
2025-07-28	54,026	511	140,861	38.4%
2025-07-25	142,768	100	237,817	60.0%
2025-07-24	180,484	10	325,283	55.5%
2025-07-23	142,919	321	298,443	47.9%
2025-07-22	119,653	0	300,129	39.9%
2025-07-21	105,920	0	250,914	42.2%
2025-07-18	129,429	36	408,572	31.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	BTEC(USD) LSE
ETF Ticker	BTEK(GBP) LSE
ETF Ticker	2B70(EUR) F
ETF Ticker	2B70.DE(EUR) CXE
ETF Ticker	BTEC.LS(USD) CXE
ETF Ticker	BTEK.LS(GBP) CXE
ETF Ticker	BTEC.L(GBP) LSE
ETF Ticker	BTEK.L(GBP) LSE